FBR analyst Vernon Bernardino, one of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) biggest bulls, is slashing the price target for the drug maker to $14.
H.C.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced financial results for the first quarter ended March 31, 2017 and provided an update on the Company’s clinical …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced that it will implement a 1-for-10 reverse stock split of outstanding shares of the Company’s common stock, together …
In a research report issued Thursday, H.C.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced financial results for the year ended December 31, 2016 and provided an update on the Company’s clinical development …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced that is has begun enrolling patients into a Phase IIa clinical study of Supinoxin™ in metastatic triple negative …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced an update on the safety and efficacy of RX-3117 in an ongoing Phase IIa clinical trial in metastatic …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company’s clinical development …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a …
